Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Enterprise Value (2019 - 2025)

Silence Therapeutics' Enterprise Value history spans 6 years, with the latest figure at -$158.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 14.58% year-over-year to -$158.9 million; the TTM value through Dec 2025 reached -$158.9 million, up 14.58%, while the annual FY2025 figure was -$158.9 million, 14.58% up from the prior year.
  • Enterprise Value for Q4 2025 was -$158.9 million at Silence Therapeutics, down from -$102.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$49.2 million in Q4 2022 and bottomed at -$186.1 million in Q4 2024.
  • The 4-year median for Enterprise Value is -$114.2 million (2025), against an average of -$120.9 million.
  • The largest annual shift saw Enterprise Value plummeted 159.4% in 2021 before it soared 50.32% in 2022.
  • A 4-year view of Enterprise Value shows it stood at -$99.1 million in 2021, then skyrocketed by 50.32% to -$49.2 million in 2022, then tumbled by 277.83% to -$186.1 million in 2024, then increased by 14.58% to -$158.9 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Enterprise Value are -$158.9 million (Q4 2025), -$102.2 million (Q3 2025), and -$114.2 million (Q2 2025).